Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Halozyme Therapeutics, Inc. HALO
$32.81
-$0.18 (-0.55%)
На 18:00, 12 мая 2023
+86.68%
Потенциал через год
Ранг: 1
Ключевые показатели
-
Marketcap
4513219719.00000000
-
week52high
59.46
-
week52low
29.85
-
Revenue
660116000
-
P/E TTM
21
-
Beta
1.21868500
-
EPS
1.40000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 20:00
Описание компании
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Goldman Sachs | Buy | Buy | 26 мая 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 11 мая 2022 г. |
| Wells Fargo | Overweight | Overweight | 24 ноя 2021 г. |
| SVB Leerink | Outperform | Outperform | 03 ноя 2021 г. |
| JMP Securities | Market Outperform | Market Outperform | 03 ноя 2021 г. |
| Morgan Stanley | Overweight | 09 сент 2022 г. | |
| SVB Leerink | Outperform | Outperform | 14 ноя 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 09 ноя 2022 г. |
| JP Morgan | Overweight | Overweight | 22 ноя 2022 г. |
| Wells Fargo | Overweight | 28 ноя 2022 г. | |
| Benchmark | Buy | Buy | 08 дек 2022 г. |
| SVB Leerink | Outperform | Outperform | 11 янв 2023 г. |
| Morgan Stanley | Overweight | Overweight | 21 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Torley Helen | D | 60000 | 10000 | 19 янв 2023 г. |
| Torley Helen | D | 587177 | 10000 | 19 янв 2023 г. |
| Torley Helen | A | 597177 | 10000 | 19 янв 2023 г. |
| Torley Helen | D | 70000 | 10000 | 18 янв 2023 г. |
| Torley Helen | D | 587177 | 10000 | 18 янв 2023 г. |
| Torley Helen | A | 597177 | 10000 | 18 янв 2023 г. |
| Torley Helen | D | 80000 | 10000 | 17 янв 2023 г. |
| Torley Helen | D | 587177 | 1103 | 17 янв 2023 г. |
| Torley Helen | D | 588280 | 8897 | 17 янв 2023 г. |
| Torley Helen | A | 597177 | 10000 | 17 янв 2023 г. |
Новостная лента
These 4 Stocks Sport Impressive Interest Coverage Ratio
Zacks Investment Research
11 мая 2023 г. в 12:11
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Companies such as Stride (LRN), ServiceNow (NOW), Halozyme Therapeutics (HALO) and AMETEK (AME) are strong enough to meet financial obligations.
Halozyme (HALO) Q1 Earnings Disappoint, Revenues Rise Y/Y
Zacks Investment Research
10 мая 2023 г. в 13:41
Halozyme (HALO) first-quarter earnings and revenues miss estimates. The company reiterates its guidance for 2023.
Halozyme Therapeutics (HALO) Q1 Earnings and Revenues Miss Estimates
Zacks Investment Research
09 мая 2023 г. в 19:07
Halozyme Therapeutics (HALO) came out with quarterly earnings of $0.47 per share, missing the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.47 per share a year ago.
Halozyme to Present at Upcoming Investor Conferences
PRNewsWire
03 мая 2023 г. в 08:30
SAN DIEGO , May 3, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the following investor conferences. Details of the presentations are as follow: Event: BofA Securities 2023 Health Care Conference Format: Corporate Presentation and 1x1 Meetings Presentation Date: Wednesday, May 10, 2023 Presentation Time: 4:20 p.m.
Halozyme's ENHANZE Technology Is The Future Of Biologics Delivery
Seeking Alpha
12 апр 2023 г. в 07:38
Halozyme Therapeutics (HALO) is a biotech company with a unique platform technology, ENHANZE, that allows for the subcutaneous delivery of biologics. Recent CMS guidance related to Medicare drug price negotiations under the Inflation Reduction Act (IRA) has caused some uncertainty among investors.